



# RanBP2-Mediated SUMOylation Promotes Human DNA Polymerase Lambda Nuclear Localization and DNA Repair

M. Moreno-Oñate<sup>1,†</sup>, A.M. Herrero-Ruiz<sup>2</sup>, M. García-Dominguez<sup>2</sup>,  
F. Cortés-Ledesma<sup>2,3</sup> and J.F. Ruiz<sup>1,2</sup>

**1** - Departamento Bioquímica Vegetal y Biología Molecular, Universidad de Sevilla, 41012 Sevilla

**2** - Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad de Sevilla/CSIC/Universidad Pablo Olavide/Junta de Andalucía, 41092 Sevilla, Spain

**3** - Topology and DNA Breaks Group, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain

**Correspondence to F. Cortés-Ledesma and J.F. Ruiz:** F. Cortés-Ledesma, Spanish National Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, 28029 Madrid, Spain; J.F. Ruiz, Universidad de Sevilla–Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Av. Américo Vespucio s/n, 41092 Sevilla, Spain. [fcortes@cnio.es](mailto:fcortes@cnio.es), [jfruiz@us.es](mailto:jfruiz@us.es)

<https://doi.org/10.1016/j.jmb.2020.03.020>

Edited by Dr M Yaniv

## Abstract

Cellular DNA is under constant attack by a wide variety of agents, both endogenous and exogenous. To counteract DNA damage, human cells have a large collection of DNA repair factors. Among them, DNA polymerase lambda (Polλ) stands out for its versatility, as it participates in different DNA repair and damage tolerance pathways in which gap-filling DNA synthesis is required. In this work, we show that human Polλ is conjugated with Small Ubiquitin-like MOdifier (SUMO) proteins both *in vitro* and *in vivo*, with Lys27 being the main target of this covalent modification. Polλ SUMOylation takes place in the nuclear pore complex and is mediated by the E3 ligase RanBP2. This post-translational modification promotes Polλ entry into the nucleus, which is required for its recruitment to DNA lesions and stimulated by DNA damage induction. Our work represents an advance in the knowledge of molecular pathways that regulate cellular localization of human Polλ, which are essential to be able to perform its functions during repair of nuclear DNA, and that might constitute an important point for the modulation of its activity in human cells.

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Cellular metabolism daily produces thousands of molecules that are able to generate a variety of DNA lesions, ranging from simple nucleotide changes to DNA breaks [1]. To deal with all DNA lesions, human cells have evolved a variety of repair mechanisms that ensure the maintenance of genome integrity at every cell cycle, avoiding the pathological consequences that might result from a defective response to DNA damage [2,3]. Short-patch DNA synthesis to fill small gaps is required in virtually all these DNA repair pathways. This gap-filling DNA synthesis is a singular reaction mainly performed by X-family specialized DNA polymerases [4], which develop their abilities in

diverse escenarios, such as base excision repair (BER) [5], the repair of or tolerance to oxidative damage [6,7], and the repair of DNA double-strand breaks (DSBs) [8–11]. Among the four PolX members identified in human cells to date, namely Polβ, terminal deoxynucleotidyl transferase, Polμ, and Polλ, the latter shows the broadest range of action in DNA repair and tolerance to DNA damage [12]. Functional versatility of Polλ suggests interaction with multiple co-factors in the different pathways in which its gap-filling activity is required, probably implying a complex regulation. In agreement to this, previous studies have revealed cell cycle and DNA damage-dependent phosphorylation-mediated regulation of human Polλ [13–15].

Post-translational modification (PTM) of proteins plays an essential role in the proper functioning and viability of eukaryotic cells. Among the different PTMs identified to date, conjugation of Small Ubiquitin-like MOdifier (SUMO) proteins seems crucial in human cells, as it plays relevant roles in key cellular processes, such as DNA replication, transcription, and general maintenance of genomic stability [16–19]. SUMOylation is a highly dynamic and transient process that promotes covalent attachment of SUMO moieties to specific lysine residues on target proteins. This reaction is reversible thanks to the existence of a variety of SUMO-specific proteases (SENPs) that efficiently remove SUMO proteins from targeted substrates [16,17]. Importantly, SUMOylation can protect proteins from ubiquitin-mediated proteasomal degradation, probably competing with ubiquitination machinery for the same target lysine residues [17,20]. In human cells, there are at least three main SUMO paralogs. SUMO1 shares approximately 45% sequence identity with SUMO2 and SUMO3, and these two are 96% identical to each other. These SUMO proteins are approximately 12 kDa in size and structurally very similar to ubiquitin [20]. SUMO substrates are mainly proteins with nuclear functions that can be modified either with a single SUMO moiety (mono-SUMO), multiple SUMO units at different sites (multi-SUMO), or SUMO chains formed at one specific target site (poly-SUMO). In this regard, SUMO paralogs also differ in their ability to form polymeric chains, as SUMO2 and SUMO3 possess internal Lys residues that can serve as SUMO acceptor sites in an auto-modification process that SUMO1 does not have [21]. Likewise, there are substantial differences in the dynamics of SUMO paralogs, because while SUMO1 is mainly found within the nucleoli, the nuclear envelope and cytoplasmic foci, SUMO2/3 are distributed throughout the nucleoplasm [22]. Moreover, whereas SUMO1 mainly exists in the protein-conjugated form, vertebrate cells have a large pool of free SUMO2/3 [22,23], which is conjugated to high-molecular-mass proteins when cells are subjected to protein-damaging stimuli [23,24]. Covalent attachment of SUMO moiety to target proteins occurs in a three-step sequential process, frequently at specific consensus sequences [16,17]. The SUMO conjugation process is initiated by covalent binding of SUMO protein to the SUMO-activating enzyme SAE1 (E1) through a thioester bond. This is followed by SUMO transfer to a second factor, Ubc9 (E2), to form an E2–SUMO1 complex. Although Ubc9 can directly transfer the SUMO to acceptor Lys residues on target protein, this reaction is facilitated *in vivo* by a group of E3 protein ligases, whose mediation is especially relevant for substrate selection in proteins lacking SUMO acceptor consensus sequences [20]. The different SUMO E3 ligases identified so far have

distinct subcellular localization, reflecting different biological functions of SUMO modification [25]. Accordingly, whereas RanBP2 is associated with the nuclear pore complex and has been related to nucleo-cytoplasmic trafficking of specific proteins [26], PIAS, Pc2/CBX4, and others are essentially found in the nucleus, where they play roles in a wide variety of biological processes, from transcription regulation and chromatin remodeling to the maintenance of cellular homeostasis and genome integrity [16,17,20].

Here we report that DNA polymerase lambda (Pol $\lambda$ ) is one of the protein targets for SUMOylation in human cells and uncover the biological role of this PTM. We identify human Pol $\lambda$  lysine 27 (K27) as the main acceptor site for the covalent attachment of SUMO proteins both *in vitro* and *in vivo*, and demonstrate that the lack of SUMOylation results in deficient import of Pol $\lambda$  into the nucleus. We also identify the role of nuclear pore complex-associated RanBP2 protein as the main E3 ligase required for Pol $\lambda$  SUMOylation in the cytoplasm, allowing its entry into the nucleus and its function during DNA repair. Overall, our work provides insights into the regulation of Pol $\lambda$  during the DNA damage response and its potential use to control the quantity and/or quality of Pol $\lambda$ -mediated DNA repair events.

## Results and Discussion

### Human Pol $\lambda$ is SUMOylated *in vitro* and *in vivo*

Analysis of human Pol $\lambda$  amino acid sequence by specialized software (SUMOplot, by Abgent; <http://www.abgent.com/sumoplot>) suggested that Pol $\lambda$  can be modified by SUMOylation. To confirm this prediction, we performed *in vitro* SUMOylation assays using purified proteins (Figure 1(a) and Supplemental Figure 1A and B). In these assays, we observed the appearance of low electrophoretic mobility species exclusively in the presence of ATP, an essential requirement for SUMO conjugation catalysis. A main modified protein showed an apparent increase in molecular weight of about 15–20 kDa with respect to unmodified protein when either SUMO1 or SUMO2 was included in the assays. This increase was in agreement with mono-SUMOylation of human Pol $\lambda$  (Figure 1(a)). Moreover, other less represented species with slightly lower electrophoretic mobility were also observed with both SUMO paralogs, suggesting that different lysine residues could be additionally targeted with SUMO, although with less efficiency (Figure 1(a)). We next analyzed whether Pol $\lambda$  SUMOylation also occurred *in vivo* by performing Ni-NTA pulldowns under denaturing conditions from human 293T cells co-expressing Flag-Pol $\lambda$ , His-

SUMO1 and Ubc9, the only known E2 conjugation enzyme in mammalian cells. In these experimental conditions, SUMOylation of human Pol $\lambda$  was very efficient, and the size of the different low electrophoretic mobility species observed suggested the formation of poly-SUMO chains (Supplemental Figure 1C). Of note, although a fraction of unmodified Pol $\lambda$  was pulled down from all samples, SUMO-Pol $\lambda$  species were strictly dependent on His-SUMO1 over-expression (Supplemental Figure 1C). Notably, Pol $\lambda$  SUMOylation was detected at endogenous levels of Ubc9 and was strongly reduced in the presence of a dominant negative Ubc9 mutant (Ubc9-C93S) that cannot catalyze SUMO conjugation to target proteins [27] (Supplemental Figure 1C). SUMOylation of Pol $\lambda$  *in vivo* was also confirmed by using engineered human U2OS cell lines stably expressing His-tagged SUMO paralogs [28,29]. These cells were transiently transfected with the plasmid encoding for Flag-Pol $\lambda$ , and SUMO conjugates were pulled down from cell extracts as described above. In these experimental conditions, efficient SUMOylation of Pol $\lambda$  was also observed both with SUMO1 and SUMO2 paralogs, being the modification undetectable in control U2OS cells with untagged SUMO proteins (Figure 1(b)). Noteworthy, poly-SUMO chain formation in these experimental conditions was prevented by the molecular features of His-tagged SUMO paralogs expressed in these engineered cells [28,29].

### Identification of Pol $\lambda$ SUMOylation sites

Our initial analysis *in silico* predicted lysine 27 (K27) as the amino acid residue with the highest probability to be targeted by SUMO moiety in human Pol $\lambda$  (Supplemental Figure 2A and B). K27 is embedded in a highly conserved non-consensus SUMOylation motif located at the most N-terminal region of the protein (AKIP, with the underlined residue being the SUMO target; Supplemental Figure 2A). This region is characterized by a great flexibility, which would be in agreement with previously reported SUMO preferential targeting to highly disordered regions [29]. We confirmed initial prediction by performing *in vitro* SUMOylation assays using peptide arrays that covered the most N-terminal region of human Pol $\lambda$ , including both K27 and all its proximal lysine residues (residues 8, 12, 15, and 23; Figure 1(c) and (d)). These assays showed the strongest SUMO targeting in peptides containing K27 (Figure 1(d)), according to proteome-wide studies that had also identified this residue as the main target for Pol $\lambda$  SUMOylation (Supplemental Figure 2C) [29]. We therefore generated the most conservative mutation of SUMO acceptor lysine (K27R mutation) and analyzed the effect on SUMOylation *in vivo*, as described above. In these assays, whereas a reduction of SUMO1 conjugation could not be detected in K27R mutant

compared to wild-type Pol $\lambda$ , an evident decrease was observed in the case of SUMO2 conjugation (Figure 1 (e) and (f)). This effect could be explained to some extent by the lower efficiency of SUMO2 conjugation compared to SUMO1, already observed *in vitro* (Figure 1(b)). Likewise, these assays suggested the existence of alternative SUMOylation target sites in Pol $\lambda$ , also in agreement with results obtained *in vitro* (Figure 1(a)) and with proteomic studies that identified K8 and K23 residues as alternative (secondary) lysines for SUMOylation in the N-terminal region (Supplemental Figure 2C) [29]. To prevent SUMOylation of these alternative sites, we generated a mutant in which all seven N-terminal lysine residues, including K8, K12, K15, K23, K27, and two additional and more distant ones (K63 and K111), were equally substituted by arginines (mutant 7KR; Figure 1(c)), and analyzed the effect of these mutations in SUMOylation of Pol $\lambda$ . Of note, all these conservative mutations are localized in the N-terminal end of Pol $\lambda$ , very far from the catalytic domain and in a protein domain that has been shown to be needless for polymerization activity. This analysis showed a dramatic decrease of SUMO conjugation efficiency in 7KR mutant compared with wild-type Pol $\lambda$ , both with SUMO1 and SUMO2 (Figure 1(e) and (f)). We obtained fully confirmation of Pol $\lambda$  K27 residue SUMO-specific targeting *in vivo* through generation of an additional mutant protein in which all N-terminal lysine residues except such K27 were mutated to arginine (mutant 6KR). Notably, this 6KR mutant fully recovered SUMOylation profile observed *in vivo* in wild-type Pol $\lambda$ , both with SUMO1 and SUMO2 (Figure 1(e) and (f)), indicating that K27 is a target for SUMOylation *in vivo*. These results do not rule out the possibility that other proximal lysine residues (i.e., K8 or K23) can play a similar role if they are available for SUMOylation. In agreement, SUMOylation of these two lysine residues has also been detected in proteomic-wide analysis, although with a lower frequency than K27 residue (Supplemental Figure 2C) [29]. It is worth noting that because SUMOylation targets lysine residues of protein substrates, it can potentially compete with other lysine-directed PTMs like acetylation or ubiquitylation [17]. Indeed, Pol $\lambda$  K27 has been identified as a target for ubiquitination, which controls Pol $\lambda$  levels during cell cycle [30]. In light of our results, it is tempting to speculate that K27 SUMOylation could antagonize the effects of ubiquitin, a competitive relationship that has been reported in many other proteins, including some DNA damage response factors [2,17].

### SUMOylation regulates subcellular localization of human Pol $\lambda$

One of the first roles assigned to SUMOylation *in vivo* is to regulate subcellular localization of some target proteins, such as RanGAP protein, the first identified SUMO substrate [31]. Therefore, we

analyzed by immunofluorescence the subcellular localization of Flag-tagged Polλ versions, including wild-type, mutants analyzed in previous *in vivo* assays (K27R, 7KR, and 6KR) and two additional mutants affecting the nearest lysine amino acid residue K23 (K23R and K23/27R) (Figure 2(a)). As expected from a DNA repair polymerase, the distribution of wild-type Polλ in human U2OS cells was predominantly nuclear (more than 92% cells). In

contrast, Polλ K27R single mutant showed a markedly different subcellular distribution, with a fraction of the protein remaining outside the nucleus (more than 25%;  $p < .01$  in ANOVA test). This effect was specific of K27 amino acid residue, as it was not observed when mutation affected K23 residue (Figure 2(a)). The abnormal distribution seen in K27R mutant was strongly exacerbated in Polλ 7KR, the mutant that was barely SUMOylated *in vivo*




Figure 1 (legend on next page)

(Figure 1(e) and (f)), which was almost completely excluded from the nucleus (Figure 2(a)). Notably, this cytoplasmic distribution was abolished when the K27 residue became available again for SUMOylation, in the 6KR mutant, completely recovering the nuclear localization observed in the wild-type Pol $\lambda$  (Figure 2(a)). These results suggest that SUMOylation at K27 residue controls Pol $\lambda$  entry into the nucleus *in vivo*. Alternatively, SUMO modification might be required to retain Pol $\lambda$  within the nucleus. To evaluate this possibility, we analyzed the effect of leptomycin B (LMB) in the subcellular localization of the Pol $\lambda$  7KR mutant protein. LMB is an inhibitor of the nuclear-cytoplasmic shuttling of proteins that contain specific nuclear export signals [32], and human Pol $\lambda$  has a predicted nuclear export signal at the BRCT domain. The presence of LMB did not have any effect on the distribution of Pol $\lambda$  K7R protein (Supplemental Figure 3), indicating that SUMOylation is not required to retain Pol $\lambda$  inside the nucleus and pointing toward a role in the translocation of Pol $\lambda$  from the cytoplasm into the nucleus. To directly confirm this hypothesis, we generated Pol $\lambda$  SUMOylation mimetic constructs and analyzed their subcellular localization by means of immunofluorescence. These constitutive SUMO-Pol $\lambda$  versions were obtained by translational fusion of mature SUMO1 or SUMO2 to the N terminus of Pol $\lambda$  K7R mutant protein (Supplemental Figure 4A). We also replaced SUMO specific C-terminal double-glycine residues by alanine residues in fusion proteins (S1-fusAA and S2-fusAA, respectively) to avoid SUMO removal due to the strong activity of SENPs *in vivo* [16] (Supplemental Figure 4A). Genetic fusion of either SUMO1-AA or SUMO2-AA to Pol $\lambda$  7KR mutant did not restore nuclear localization of Pol $\lambda$  (Supplemental Figure 4B), suggesting that the presence of SUMO moiety in the N terminus of Pol $\lambda$ , although necessary, is not enough to facilitate its entry

into the nucleus. Nevertheless, given that both dynamism and reversibility are essential for cellular roles of SUMOylation, it is very likely that these fusion proteins might be incompatible with nucleocytoplasmic shuttling functions. A defect in the proper and functional folding of fusion proteins cannot be ruled out either. Regardless, our study uncovers the pivotal role of SUMOylation in the control of cellular distribution of Pol $\lambda$ , and identify the molecular basis of previous observations that Pol $\lambda$  catalytic core, a protein version lacking the amino terminal region including BRCT and Ser-Pro rich domains, is not able to enter into the nucleus [33,34].

### Lack of SUMOylation results in decreased Pol $\lambda$ recruitment to etoposide-induced DNA damage

Given its relevance in the nuclear localization of Pol $\lambda$ , we wanted to determine the consequences of interfering with SUMOylation on its recruitment to DNA lesions. To specifically measure Pol $\lambda$  recruitment to DNA damage, we developed an experimental approach based on proximity ligation assays (PLAs) that uses specific antibodies for human Pol $\lambda$  and phosphorylated histone H2AX ( $\gamma$ H2AX), a well-known marker of DNA damage in mammalian cells [35,36]. We validated the use of this molecular tool to measure the recruitment of Pol $\lambda$  to DNA damage sites *in vivo* by analyzing the formation of PLA foci of endogenous  $\gamma$ H2AX and Pol $\lambda$  in human U2OS cells treated with etoposide. In these experimental conditions, we observed an increase in the number of PLA foci that was directly proportional to the dose of etoposide used (Supplemental Figure 5). Once validated the assay, we performed additional experiments in U2OS cells that were pre-treated with specific siRNAs to remove endogenous Pol $\lambda$ , and that concomitantly overexpressed similar levels of

**Figure 1.** SUMOylation of human Pol $\lambda$ . (a) *In vitro* SUMOylation reactions with indicated purified human proteins were carried out as described in [Materials and Methods](#). Proteins were resolved by SDS-PAGE and immunoblotted (IB) with anti-Pol $\lambda$  antibody. Unmodified and SUMO-conjugated Pol $\lambda$  are indicated. (b) U2OS cells stably expressing either His-SUMO1 or His-SUMO2 were transiently transfected with empty or Flag-Pol $\lambda$  encoding vectors. His-SUMO conjugates were pulled down on Ni-NTA beads (Ni-PD) under denaturing conditions ([Materials and Methods](#)) and IB with anti-Flag antibody. Expression of Flag-Pol $\lambda$  was monitored by immunoblotting of cell lysates (input). An U2OS cell line without genomic integration of tagged SUMO proteins was assayed in parallel as a control of specificity. Unmodified and SUMO-conjugated Flag-Pol $\lambda$  are indicated. *M* denotes the molecular mass markers in kDa. (c) Human Pol $\lambda$  domain organization. Main conserved PolX domains [42] and the localization of putative SUMO acceptor lysines in the N-terminal region are indicated. (d) Identification of SUMO conjugation sites using peptide arrays. Peptides are numbered sequentially from the starting Met (M) codon. Each spot in the array represents Pol $\lambda$ -derived peptides formed by the indicated consecutive residues with 10-amino-acid overlap with the previous peptide. Polarity of peptides with respect to membrane attachment is indicated with an arrow. K27 is indicated in green, and neighbor lysines are marked in bold. The peptide array was subjected to an *in vitro* SUMOylation assay as described in [Materials and Methods](#) and then immunoblotted with anti-SUMO1 antibody (right panel). Positive SUMO-conjugated peptides generated dark spots, whereas non-conjugated peptides leave blank spots. Left panel represents Ponceau staining of the array. (e, f) U2OS cell lines with integrated His-SUMO1 (e) or His-SUMO2 (f) were transiently transfected either with wild-type Flag-Pol $\lambda$  or Flag-Pol $\lambda$  K27R, 7KR, and 6KR mutants. His-SUMO conjugates were pulled down on Ni-NTA beads (Ni-PD) as in (b) and IB with anti-Flag antibody. Expression of Flag-Pol $\lambda$  variants was monitored by immunoblotting of cell lysates (input). Unmodified and SUMO-conjugated Flag-Pol $\lambda$  are indicated.

siRNA-resistant versions of either wild-type Pol $\lambda$  or Pol $\lambda$  7KR mutant (Figure 2(b)). In these experimental conditions, U2OS cells expressing wild-type Pol $\lambda$  showed an increase in Pol $\lambda$ - $\gamma$ H2AX PLA foci in response to etoposide-induced DNA damage (untreated WT median 8.0 *versus* etoposide-treated WT median 47.5; 6-fold increase,  $p < .001$ , ANOVA test) (Figure 2(c)). Notably, U2OS cells expressing Pol $\lambda$

7KR mutant showed a decrease in Pol $\lambda$ - $\gamma$ H2AX PLA foci after etoposide-induced DNA damage with respect to wild-type Pol $\lambda$  (WT median 47.5 *versus* 7KR median 18; 3-fold decrease,  $p < .001$ , ANOVA test) (Figure 2(c) and (d)). These results indicate that recruitment of Pol $\lambda$  to etoposide-induced DNA damage sites is reduced when its SUMOylation-mediated entry into the nucleus is impeded. Noteworthy, some




Figure 2 (legend on next page)

Pol $\lambda$ - $\gamma$ H2AX PLA signal is still observed in cells expressing Pol $\lambda$  7KR (etoposide 7KR median 18 *versus* untreated 7KR median 5) (Figure 2(c)), although etoposide treatment did not largely change the distribution of this mutant protein (Supplemental Figure 6). This is indicative that some Pol $\lambda$  has to be into the nucleus, which can probably be due to incomplete silencing of POLL expression.

However, alternative routes or complementary mechanisms for Pol $\lambda$  nuclear entry and recruitment to DNA damage sites, independently of the SUMO-mediated pathway, cannot be excluded. Accordingly, novel interactions between Pol $\lambda$  NLS-derived peptides and cellular importins have been recently described [37]. Future studies, both structural and functional, will clarify these alternative pathways and putative synergies with the findings uncovered in our study.

### RanBP2 E3 ligase mediates Pol $\lambda$ SUMOylation and nuclear localization

SUMOylation of natural substrates *in vivo* is facilitated by a variety of E3 protein ligases, especially in proteins, as Pol $\lambda$ , lacking consensus SUMO acceptor motifs [16,25]. To date, the only non-nuclear E3 ligase identified is nuclear pore complex-associated RanBP2 protein, which can form a stable complex with both SUMO1 and Ubc9 throughout the cell cycle and promote the last step in the SUMOylation process [38–40]. Considering this, and the nucleo-cytoplasmic shuttling defect seen in our Pol $\lambda$  mutants (Figure 2(a)), we reasoned that RanBP2 could be the E3 ligase involved in Pol $\lambda$  SUMOylation. Supporting this possibility, PLAs detected physical proximity between RanBP2 and Pol $\lambda$  predominantly in the outer side of nuclear

envelope (Figure 3(a) and Supplemental Figure 7). Moreover, we detected direct interaction of these two proteins by co-immunoprecipitation in the absence of any external stimulus (Figure 3(b)), suggesting that Pol $\lambda$  might be targeted for RanBP2-mediated SUMOylation constitutively. To verify a functional interaction between RanBP2 E3 ligase and Pol $\lambda$ , we performed His-SUMO pulldown assays as those described above in U2OS cells that were previously treated with RanBP2-specific siRNAs. In these experimental conditions, we observed that the reduction in RanBP2 expression led to a strong concomitant decrease in conjugation of SUMO to Pol $\lambda$  (Figure 3(c) and (d)). This effect was not seen in cells treated with control non-targeting siRNAs, so that confirmed RanBP2 as the main E3 ligase involved in Pol $\lambda$  SUMOylation. In the same way, immunofluorescence assays performed in Flag-Pol $\lambda$  expressing U2OS cells that had been silenced for RanBP2 expression also showed a strong decrease of Flag-Pol $\lambda$  nuclear localization when compared to cells treated with control non-targeting siRNAs (Figure 3(e); more than 40% reduction in nuclear localization;  $p < .001$  in an unpaired *t*-test). These results were in fully agreement with those obtained with non-SUMOylatable Pol $\lambda$  mutants in our *in vivo* SUMOylation assays (Figure 2(a)). Altogether, our results indicate that RanBP2 is the main E3 ligase participating in SUMO-mediated modification of human Pol $\lambda$  to promote its nuclear import. Of note, nuclear import of artificial cargos can still occur *in vivo* in RanBP2-depleted cells, although rates are substantially reduced [26]. This could explain residual nuclear Pol $\lambda$  observed in our analyses with K27R single mutant (Figure 2(a)) and, again, suggest the existence of SUMO-independent pathways, still to

**Figure 2.** Subcellular localization of Pol $\lambda$  is controlled by SUMOylation. (a) Human U2OS cells were transiently transfected with different Flag-Pol $\lambda$  versions (either WT or K23R, K27R, K23/27R, 7KR, or 6KR mutants), and subcellular localization of Pol $\lambda$  was examined by immunofluorescence using anti-Flag antibody (red). Nuclei were stained with DAPI (blue). Merge of both Flag and DAPI signals is also shown. Pol $\lambda$  expressing cells were blindly scored for their Pol $\lambda$  subcellular localization, and classified in one of the following three categories: mainly nuclear, equally distributed between nucleus, and cytoplasmic (Nuc  $\approx$  Cyto) or mainly cytoplasmic. Representative images for each condition are shown in the left panel. The experiment was performed three independent times, with more than 100 independent cells counted each time. The mean percent localization of each condition is plotted, and error bars represent the SD of each data set. ANOVA was used to test for significance in subcellular localization of Pol $\lambda$  variants (\*\*,  $p < .01$ ; \*\*\*,  $p < .001$ ). (b) Human His-SUMO1 U2OS cells were treated with specific POLL siRNAs, as previously described [15], and then transiently co-transfected with either Flag-empty vector or siRNA-resistant versions of Flag-Pol $\lambda$  (WT and 7KR). Resistance to siRNA-mediated silencing was confirmed by immunoblotting (IB) with anti-Pol $\lambda$  antibody (green). Immunoblotting with anti-tubulin (red) was used as a loading control. (c) Human His-SUMO1 U2OS cells treated as in (b) were subjected or not to etoposide treatment (20  $\mu$ M, 30 min) and processed for PLA using anti-Pol $\lambda$  and anti-phosphoH2AX ( $\gamma$ H2AX) antibodies. PLA foci (red) were counted in transfected cells. Plots display the median values (black bar) for nuclear  $\gamma$ H2AX/Pol $\lambda$  PLA foci in each experimental condition (untreated WT, 8.0; untreated 7KR, 5.0; etoposide WT, 47.5; etoposide 7KR, 18.0) plus interquartile range (25th and 75th percentiles). The statistical significance was calculated using GraphPad Prism 5.0;  $p < .001$  in one-way ANOVA test of three independent experiments, with >35 individual cells analyzed for each condition in each independent repeat (total number of cells scored: WT untreated, 147; 7KR untreated, 122; WT etoposide, 127; 7KR etoposide, 108). (d) Representative images of one experiment described in (c).  $\gamma$ H2AX/Pol $\lambda$  PLA foci are shown in red. Flag-Pol $\lambda$  transfected cells (in green) were identified by performing post-PLA staining by using secondary A488-conjugated anti-rabbit antibodies. Nuclei are stained with DAPI (blue).

be deciphered, through which Pol $\lambda$  could enter into the nucleus.

### Pol $\lambda$ SUMOylation is enhanced after MMS-mediated DNA damage induction

Once demonstrated the involvement of RanBP2-dependent SUMOylation at the nuclear pore complex

in the translocation of Pol $\lambda$  into the nucleoplasm, we wanted to determine if this molecular mechanism was affected by DNA damage. By using engineered human U2OS cell lines stably expressing His-tagged SUMO paralogs described above, we were able to efficiently detect SUMOylation of endogenous Pol $\lambda$  in Ni-NTA pull down assays (Figure 4(a)). This allowed us to evaluate the effect of DNA damage induction on




Figure 3 (legend on next page)


Pol $\lambda$  SUMOylation in more physiological conditions. Such analysis revealed an increase of Pol $\lambda$  SUMOylation when cells were subjected to DNA damage induction, being the increase especially evident in response to the DNA alkylating agent methyl methanesulfonate (MMS) (Figure 4(b) and (c)). MMS-induced DNA lesions are mainly repaired by BER, a repair pathway in which DNA polymerase  $\beta$  is the main gap-filling DNA polymerase [41,42]. Although Pol $\lambda$  participation in this repair route was initially suggested as a *back-up* mechanism in mouse cells [43], it has also been shown that cells deficient in both Pol $\lambda$  and Pol $\beta$  are hypersensitive to MMS [5], suggesting that both PolX enzymes synergistically participate in the repair of a common set of DNA lesions. Interestingly, it has been recently reported that human Pol $\lambda$  can also perfectly complement the absence of Pol $\beta$  in POLB-deficient cell extracts, leading authors to suggest that Pol $\lambda$  might be sequestered *in vivo* in a complex with other proteins or post-translationally modified in a way that limits its ability to participate effectively in BER in normal conditions [44]. Overall, our results would be in agreement with a model in which, if Pol $\beta$  is overcome by the amount of damage generated by MMS, a greater requirement of nuclear Pol $\lambda$  would be needed, which might be achieved through the SUMO-mediated translocation of Pol $\lambda$  into the nucleus. It is worth noting that main SUMOylation site in Pol $\lambda$  (K27 residue) is, in turn, target site for ubiquitination, which is a signal for its subsequently degradation *via* proteasome [30]. Therefore, it cannot be ruled out that SUMOylation at K27 makes Pol $\lambda$  more stable and therefore more active in the repair of MMS-induced damage. Future studies will be necessary to validate this model and elucidate the precise role of Pol $\lambda$  SUMOylation in BER regulation. On the other hand, it

is equally noteworthy that MMS produces a wide variety of DNA lesions, some of which prevent the progression of replication forks [45]. Therefore, one possibility would be that the increase in Pol $\lambda$  SUMOylation in response to MMS is related to replication forks problems. In agreement with this, replicative stress induced with hydroxyurea (HU) also caused a concomitant increase in SUMOylation of Pol $\lambda$  (Figure 4(c) and Supplemental Figure 8). In spite of this, we did not detect significant differences in Pol $\lambda$  SUMOylation at different stages of a cell cycle in human U2OS cells (Figure 4(d)). Overall, our data suggest that SUMOylation is a relevant signal for human Pol $\lambda$  to entry the nucleus in situations where its gap-filling activity can be especially required, e.g., during MMS-triggered BER or upon replicative stress.

## CONCLUDING REMARKS

Detailed knowledge of the post-translational regulation of DNA repair proteins is essential to understand how cells deploy the complicated and tangled network of processes that constitute the DNA damage response. Finely coordinated functioning of this complex network will determine cell viability and prevent the development of age-related diseases and cancer. In particular, it is of great interest to decipher the molecular mechanisms that allow DNA repair factors to enter the nucleus and accomplish their functions, which can have negative consequences for the cell, for example, contributing to tumorigenesis as a consequence of inefficient DNA repair [46]. In this work, we have identified SUMOylation as a novel PTM of human DNA repair polymerase lambda (Pol $\lambda$ ) with a relevant influence in its potential functionality *in vivo*. We have uncovered that SUMO

**Figure 3.** Physical and functional interaction of RanBP2 and Pol $\lambda$  at the nuclear envelope. (a) Human U2OS cells were transiently co-transfected with a plasmid encoding for HA-RanBP2 together with either Flag-POLL WT or Flag-empty (ev) vectors. PLAs were performed by using mouse monoclonal anti-RanBP2 and rabbit anti-Pol $\lambda$  antibodies. Subcellular localization of PLA foci (red) was detected by using confocal laser scanning microscopy, and nuclei were stained with DAPI (blue). X/Z views are shown in upper and middle panels, with merged images included in the right panels; an X/Y view is also shown in bottom panels, only with Flag-Pol $\lambda$  WT transfected cells. The scale bars represent 10  $\mu$ m. (b) Human 293T cells were transiently transfected as in (a), and HA-RanBP2 was immunoprecipitated 24 h later with anti-HA antibody. Recovered immunocomplexes were analyzed in 4–20% SDS-PAGE and immunoblotting with anti-HA, anti-Flag, and anti-tubulin antibodies. (c) Human His-SUMO1 U2OS cells were treated either with control (luciferase) or RanBP2 siRNAs and 24 h later transiently transfected with Flag-POLL WT vector. SUMO-Pol $\lambda$  conjugates were pulled down on Ni-NTA beads under denaturing conditions at indicated times post-transfection and immunoblotted with anti-Flag antibody (upper panel). Expression of RanBP2, Flag-Pol $\lambda$  and tubulin was monitored by immunoblotting of cell lysates with the corresponding antibodies (input). (d) Human His-SUMO1 U2OS cells were treated as in (c) and pulled down on Ni-NTA beads under denaturing conditions performed 48 h after vector transfection. Quantification represents percentage of SUMOylated Pol $\lambda$  in cells (mean value  $\pm$  standard deviation, SD) for each condition analyzed in three independent experiments. Statistical significance was determined by using an unpaired *t*-test. (e) Human His-SUMO1 U2OS cells were treated as in (c), and subcellular localization of Flag-Pol $\lambda$  was examined by immunofluorescence using anti-Flag antibody (red). Nuclei were stained with DAPI (blue). Representative images of one experiment are shown. The scale bars represent 25  $\mu$ m. Quantification represents percentage of nuclear Pol $\lambda$  in cells (mean value  $\pm$  standard deviation, SD) for each condition analyzed in three independent experiments, with more than 50 individual cells analyzed for each condition in each independent repeat. Statistical significance was determined by using an unpaired *t*-test.



**Figure 4.** Increased SUMOylation of Polλ in response to DNA damage. (a) His-SUMO1 and -SUMO2 U2OS cells were grown in p100 dishes until 80% confluence and then harvested. His-SUMO conjugates were pulled down on Ni-NTA beads (Ni-PD) under denaturing conditions, and endogenous SUMO-Polλ was detected by immunoblotting (IB) using anti-Polλ antibody. Expression of Polλ and tubulin was monitored by immunoblotting cell lysates (input) with the corresponding antibodies. (b) His-SUMO2 U2OS cells were grown as described in (a) and either mock-treated or treated with etoposide (20 μM, 30 min), hydrogen peroxide (750 μM, 1 h), MMS (0.03%, 30 min), and HU (2 mM, 2 h) before harvesting. His-SUMO conjugates were pulled down on Ni-NTA beads (Ni-PD), and endogenous SUMO-Polλ was detected as described in (a). Expression of Polλ and tubulin was monitored by immunoblotting of cell lysates (input) with the corresponding antibodies. DNA damage induction was confirmed by immunoblotting of cell lysates (input) with anti-phosphorylated H2AX (γH2AX) antibody. (c) His-SUMO2 U2OS cells were grown as in (a) and treated with increasing doses of either MMS (0.01%, 0.02%, and 0.03%, 30 min) or HU (3 and 5 mM, 2 h). His-SUMO conjugates were detected as described above. Expression of Polλ and tubulin was monitored, and replicative stress induction was confirmed with anti-phosphorylated (S4/S8) RPA antibody. (d) His-SUMO2 U2OS were synchronized in G1 by using thymidine block, as previously described [56]. Thymidine block was released from G1-enriched cultures, and His-SUMO conjugates were pulled down at different times as indicated in (a). Recovering times were selected according to González-Prieto *et al.* [56]. Cell progression at different stages of the cell cycle was monitored by immunoblotting with anti-cyclin A and E antibodies, and expression of Polλ and tubulin was monitored as described before.

modification fundamentally occurs at N-terminal K27 amino acid residue and requires E3 activity ligase from RanBP2, a nucleoporin present in the outer side of the nuclear envelope. Likewise, we have discov-

ered that nuclear localization of human Polλ is SUMO-dependent, so that such modification is required for Polλ to be recruited to DNA lesions to perform its function. It is worth noting that transport pathways may

offer attractive therapeutic targets, as they represent a very selective way of canceling a biological activity without affecting others. Consequently, the nature of the molecular pathway described here suggests that preventing Pol $\lambda$  SUMOylation by using small-molecule inhibitors of this specific modification (e.g., blocking SUMO-acceptor sites) could be a suitable point to abolish its polymerase activity in the nucleus, which could be interesting in order to explore the effect of selective Pol $\lambda$  inhibition on tumor cell growth. High levels of replicative stress and excess of oxidative lesions (i.e., ROS) are a hallmark of tumor cells that will demand a great functioning of BER and DNA damage tolerance pathways. Disrupting the cellular mechanisms that cope with this aberrant situation, for example, by inhibiting the ATR or Chk1 kinases, constitutes a very promising strategy for cancer treatment [47,48]. Interestingly, the suppression of Pol $\lambda$  activity induces synthetic lethality when combined with Chk1 inhibitors [49], what turns Pol $\lambda$  and its nucleo-cytoplasmic shuttling as additional potential chemotherapeutic target to be analyzed in more detail. Importantly, targeting the N-terminal region of Pol $\lambda$  would solve undesired effects of many of Pol $\lambda$  inhibitors identified so far, which can also affect other polymerases, in particular those from PolX family, due to high similarity in their catalytic center [50,51]. Although further structural studies should be needed to gain molecular insights of Pol $\lambda$  N-terminal region, some pioneering work performed with the murine ortholog already shed some light in this regard [33]. Finally, another attractive scenario to be explored regarding Pol $\lambda$  SUMOylation inhibition would be related to CRISPR–Cas-based gene editing tools. These systems strongly rely on the processing of directed DSBs by the cellular NHEJ repair machinery. The possibility of controlling CRISPR-based gene editing accuracy by pharmacological modulation of the repair process is being intensively evaluated at present [52]. In this regard, the search for selective inhibitors against Pol $\lambda$  SUMOylation could also be useful in the gene editing toolkit, given that a large subset of breaks generated by CRISPR–Cas systems requires specialized DNA gap-filling activity by PolX polymerases as Pol $\lambda$  [53,54].

## Materials and Methods

### Cell cultures

Human embryonic kidney 293T cells and human osteosarcoma cells (U2OS, U2OS HIS-SUMO1 and -SUMO2 expressing cells) [28,29] were cultured in Dulbecco's modified Eagle's medium medium (Sigma) supplemented with 10% fetal bovine serum (Sigma), 2 mM L-glutamine, and antibiotics (100 units/ml penicillin, 100  $\mu$ g/ml streptomycin; Sigma) at 37 °C in a

humidified atmosphere containing 5% CO<sub>2</sub>. Transient transfections of plasmids were performed with Lipofectamine (Life Technologies) according to the manufacturer's instructions.

### Plasmid constructs and siRNA

Wild-type POLL cDNA was amplified by PCR and cloned in the p3xFlag-Myc-CMV expression vector (Sigma) as previously described [15]. POLL mutants were generated by site-directed mutagenesis using p3xFlag-[POLL]-Myc-CMV and overlap extension PCR methodology with oligonucleotides listed in Table S1. POLL K6R mutant was generated by site-directed mutagenesis that reverted K27R mutation from p3xFlag-[POLL 7KR]-Myc-CMV plasmid, and both Pol $\lambda$  and Pol $\lambda$ 7KR siRNA-resistant clones were generated by using the oligonucleotides indicated in Table S1 using the p3xFlag-[POLL]-Myc-CMV and p3xFlag-[POLL 7KR]-Myc-CMV plasmids, respectively. All mutated cDNAs were verified by DNA sequencing. Constitutive SUMO-Pol $\lambda$  versions (both with SUMO1 and SUMO2) were generated by PCR amplification of either SUMO1 or SUMO2 cDNA by using oligonucleotide primers with flanking *Bgl*II cut sites (see Table S1). PCR products were digested with *Bgl*II, cloned into p3xFlag-[POLL]-Myc-CMV expression vector and sequenced to verify proper orientation of fusion cDNAs. Site-directed mutagenesis of the C-terminal di-glycine motif of SUMO proteins was performed on these plasmids by using oligonucleotides listed in Table S1 and overlap extension PCR methodology. Efficient silencing of endogenous POLL and RANBP2 genes was achieved by two consecutive rounds of transfection of previously validated double-stranded siRNAs (Table S1) [15] into human U2OS cells. Once seeded, cells were cultured for 24 h and then transfected either with control (luciferase), POLL, or RanBP2-specific siRNAs by using RNAiMAX (Life Technologies) following the manufacturer's instructions. Twenty-four hours later, cells were subjected to a second siRNA transfection with the same siRNAs and, when indicated, either p3xFlag-[POLL]-Myc-CMV expression vector or the corresponding control empty vector using Lipofectamine2000 (Life Technologies) according to the manufacturer's instructions. Silencing was confirmed by Western blotting analysis. The siRNA resistant wild-type Flag-POLL was previously described [15], and siRNA-resistant clones of Flag-POLL 7KR were obtained by using oligonucleotides listed in Table S1 and Q5 Site-Directed Mutagenesis kit (NEB) following the manufacturer's instructions.

### Proteins and *in vitro* SUMOylation assays

Mouse Ubc9, Aos1, and Uba2 were produced in *Escherichia coli* DH5 $\alpha$  at 20 °C as GST fusions and

purified with Glutathione Sepharose 4B beads (GE, Healthcare) according to the manufacturer's instructions. In the case of Ubc9, GST moiety was excised by using the PreScission protease (GE, Healthcare). Human DNA polymerase lambda (Pol $\lambda$ ) was a gift of Dr. Luis Blanco (CBM-SO, Madrid, Spain). *In vitro* SUMOylation assays with murine SUMO proteins were performed with 300 ng of purified Pol $\lambda$ . The reaction was carried out in 20  $\mu$ l of standard SUMO reaction buffer (20 mM Hepes (pH 7.5), 50 mM NaCl, 4 mM MgCl<sub>2</sub>, 0.05% Tween, and 1 mM DTT buffer) containing 200 ng Aos1/Uba2 mix (E1), 600 ng Ubc9 (E2), and 250  $\mu$ M of the corresponding SUMO protein. Reactions were initiated with 250  $\mu$ M ATP, incubated at 30 °C for 3 h, and stopped with  $\beta$ -mercaptoethanol containing Laemmli buffer. Reactions with human SUMO proteins were performed using 500 ng of purified human Pol $\lambda$  and commercially available *in vitro* SUMOylation kits (Boston Biochemicals), following the manufacturer's instructions. After *in vitro* reactions, proteins were run in SDS-PAGE 10% and immunoblotted by using anti-Pol $\lambda$  antibody (A301-640A Bethyl).

#### *In vitro* SUMOylation on peptide arrays

For *in vitro* SUMOylation assays on peptide-scanning arrays, N-terminal acetylated overlapping dodecapeptides covering the N-terminal region of human Pol $\lambda$  were generated by automated spot synthesis onto an amino-derivatized cellulose membrane (CNB Proteomics Core Facility, Proteored, Spain). Peptides were immobilized by their C-termini *via* a polyethylene glycol spacer. Overlapping peptides were spotted onto membrane so that they shared 10 amino acids with its adjacent peptide on the array, corresponding to a change of 2 amino acids per peptide. Peptide array membrane was blocked overnight in 1% bovine serum albumin (BSA) and 3% Tween-20 before SUMO-conjugation on cellulose-bound peptides. Briefly, enzymatic reaction was performed in a reaction mixture containing 5 mM ATP, 50 mM NaCl, 5 mM MgCl<sub>2</sub>, 0.2 M DTT, 1% BSA, and 3% Tween-20, and 0.15  $\mu$ M E1, 0.20  $\mu$ M E2, and 0.4  $\mu$ M SUMO1 proteins for 30 min at 37 °C. Nonspecifically bound proteins were washed off by sonication for 2 min in a bath containing 1% SDS, 0.1%  $\beta$ -mercaptoethanol, and 100 mM Na<sub>2</sub>HPO<sub>4</sub>. Further nonspecific binding was blocked by incubation with 3% BSA–1% Tween-20 in TBS for 1 h. Subsequently, the membrane was incubated for 2 h with anti-SUMO1 primary antibody diluted in blocking solution (1:1000 dilution). Membranes were washed with TBS–Tween-20 (0.1%) and subsequently incubated with HRP-conjugated secondary antibody diluted in blocking solution for 1 h. Membranes were washed extensively with TBS–T (0.1%), and SUMO1 signal was detected by ECL incubation following the manufacturer's instructions.

#### Immunoblotting, immunoprecipitation, and pulldown assays

For Western blotting analyses,  $2.5 \times 10^5$  human 293T cells were seeded per well in six-well dishes, cultured for 24 h, and transfected with the corresponding plasmids/siRNAs using Lipofectamine 2000. Cells were washed with cold phosphate-buffered saline (PBS) and collected by low-speed centrifugation. Cells were then lysed in 500  $\mu$ l lysis buffer (20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 2 mM EDTA, 1% NP-40, 1 mM PMSF, protease inhibitor cocktails (Sigma), and 1 mM DTT), homogenized, and incubated on ice for 30 min. Lysates were cleared by centrifugation at 13,000 rpm for 20 min at 4 °C, and proteins were resolved by 10–12% SDS-PAGE. For RanBP2 detection, proteins were resolved by 4–20% gradient SDS-PAGE gels (Biorad). In any case, proteins were transferred onto Immobilon-FL PVDF membranes (Millipore) by using a wet-transfer system (Biorad) at 150 mA and 4 °C for 2 h. Immunoblotting was performed according to Odyssey LI-COR Biosciences instructions. The following primary antibodies were used for immunoblotting analysis: mouse monoclonal anti-Flag (M2, Sigma), mouse anti-tubulin (T9026, Sigma), rabbit anti-Pol $\lambda$  (A301-640A, Bethyl), and mouse monoclonal anti-RanBP2 antibody (sc-74,518, Santa Cruz). After washes with TBS–0.1% Tween-20, membranes were incubated with the corresponding IRDye 800CW/680RD secondary antibodies (LI-COR Biosciences; 1/15,000) supplemented with 0.1% Tween-20, washed again and were allowed to dry to be then analyzed in Odyssey infrared imaging system with the ImageStudio Odyssey CLX Software (LI-COR). Quantification of relative band intensities was carried out using ImageJ software. For immunoprecipitations, 293T cells were cultured as before and co-transfected with both p3xFlag-POLL-Myc-CMV and HA-RanBP2 plasmids using Lipofectamine 2000 according to the manufacturer's instructions. After 24 h, cells were harvested, lysed in 500  $\mu$ l lysis buffer, and incubated on ice for 30 min. Lysates were cleared by centrifugation as indicated before, and input samples were saved for subsequent analysis. Remaining supernatants were incubated with mouse monoclonal anti-HA antibody (Sigma) overnight at 4 °C. Immuno-complexes were then incubated with Protein G-coupled Dynabeads (Life Technologies) for 4 h with end-to-end mixing at 4 °C. Beads were washed twice in lysis buffer, and bound immuno-complexes were released by boiling samples in Laemmli buffer. Proteins were resolved by 4–20% gradient SDS-PAGE gels (Biorad) and processed for Western blotting as indicated before. Input lysate (10%) was loaded alongside unless otherwise stated. For Histagged SUMO pulldown assays,  $3 \times 10^5$  human

U2OS HIS-SUMO1- and -SUMO2 expressing cells were seeded in P60 dishes, cultured for 24 h and then transfected with 3xFlag-POLL-Myc-CMV expression vectors as indicated before. After 48 h, cells were washed and collected by centrifugation in ice-cold PBS and stored until processing. For pull-down assays to detect endogenous SUMOylation of Pol $\lambda$ , cells were seeded in P100 dishes and  $2 \times 10^6$  to  $4 \times 10^6$  cells were processed. In any case, cell extracts were then prepared under denaturing conditions by incubation in 500  $\mu$ l of urea lysis buffer (8 M urea, 0.1 M Tris/HCl (pH 6.8), 0.2% Triton-X100) for 30 min with rotation at room temperature. Lysates were cleared by centrifugation at 13,000 rpm for 10 min at room temperature. Input samples were saved and His-tagged SUMO-conjugated proteins were pulled down from cell extracts by using Ni-NTA agarose beads (Life Technologies). Pulled-down proteins were washed three times in lysis buffer supplemented with 10 mM imidazole and finally eluted in lysis buffer supplemented with 250 mM imidazole and Laemmli buffer. Eluted SUMO-conjugated proteins were boiled and loaded onto 10% SDS-PAGE. Input lysate (5%) was loaded alongside unless otherwise stated. When indicated, cells were treated with different drugs and DNA damaging agents: etoposide, hydrogen peroxide, MMS, and HU (Sigma). After treatment, cells were rinsed using PBS and processed as indicated before.

### Immunofluorescence

For standard immunofluorescence studies, approximately  $2 \times 10^4$  U2OS cells were seeded onto sterile glass coverslips in each well of a four-well dish, cultured for 24 h, and transfected with Flag-POLL constructs as described above. For immunofluorescence studies involving siRNA-mediated silencing of endogenous Pol $\lambda$  or RanBP2,  $2.5 \times 10^4$  U2OS cells were seeded onto sterile glass coverslips in each well of a four-well dish and cultured for 24 h. Silencing of endogenous POLL or RANBP2 was performed as described above. After 72 h, cells were fixed by treatment with 4% formaldehyde in PBS at room temperature for 10 min, and then permeabilized by treatment with 0.2% Triton X-100 in PBS. Cells were incubated with PBS–1% BSA for 30 min to block non-specific antigens, and then were incubated with mouse monoclonal anti-Flag M2 (Sigma; 1/5000) diluted in PBS–1% BSA. After washes with PBS–0.1% Tween-20, cells were incubated with Alexa 594 Fluor-conjugated secondary antibodies (Jackson; 1/1000) and washed again as described above. Finally, they were counterstained with 4,6 diamidino-2-phenylindole (DAPI 1  $\mu$ g/ml; Sigma) and mounted using Vectashield mounting medium (Vector Laboratories). Samples were visualized and pictures taken by using a Leyca DM6000B fluorescence microscope with a HCX PL APO 63x/NA 1.40 oil immersion objective. For PLAs, human U2OS cells

were grown on sterile glass coverslips and co-transfected with both HA-RanBP2 and Flag-Pol $\lambda$  as described before. For PLA assays to analyze and measure endogenous Pol $\lambda$  and  $\gamma$ H2AX proximity, transfection step was omitted. After 48 h, cells were fixed and permeabilized as described above. PLA assays were performed using the Duolink PLA kit (Sigma) according to the manufacturer's instructions with following antibodies: rabbit anti-Pol $\lambda$  (A301-640A Bethyl; 1/1000), mouse monoclonal anti-RanBP2 antibody (sc-74,518, Santa Cruz; 1/1000), and mouse monoclonal anti- $\gamma$ H2AX (clone JBW301, Millipore; 1/1000). For PLA assays measuring transfected Flag-Pol $\lambda$  (either si-RNA-resistant WT or 7KR mutant) and  $\gamma$ H2AX proximity, positively transfected cells were identified by performing post-PLA staining by using Alexa A488 fluor-conjugated anti-rabbit secondary antibodies (Jackson; 1/1000). After final wash step, cells were counterstained with DAPI and mounted as described above. Confocal analysis was performed with a Leica confocal microscope TCS SP5, using a HCX PL APO lambda blue 63  $\times$  1.4 objective with zoom 3. Image stacks were captured keeping a step size of 0.5  $\mu$ m, and sequential scanning was defined for each channel using 543, 488, and 405-nm laser lines, respectively.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jmb.2020.03.020>.

---

### Acknowledgments

The authors thank A. Vertegaal (Leiden University Medical Center, The Netherlands) for U2OS expressing His-SUMO1 and -2 cell lines, and L. Blanco (CBM-SO CSIC/UAM, Spain) for purified human Pol $\lambda$ .

### Author contributions

J.F.R. conceived and designed the research; M.M. O., A.H.R., M.G.D., and J.F.R. performed the experiments, collected, and analyzed; F.C.L. provided scientific input and designed the research; J.F.R. wrote the manuscript with input from all authors.

### Conflict of interest

The authors declare no competing interests.

### Funding

This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) and the European Commission (European Regional Development Fund) to J.F.R.

(BFU2013-44343-P) and to F.C.L. (SAF2014-55532-R), and grants from the Universidad de Sevilla to J.F.R. (PP2017-8488, PP2018-10807). J. F.R. was the recipient of a Ramón y Cajal contract from the Spanish Ministry of Economy and Competitiveness (MINECO; RYC-2011-08752).

Received 10 January 2020;

Received in revised form 17 March 2020;

Accepted 19 March 2020

Available online 26 March 2020

**Keywords:**

DNA polymerase lambda;  
DNA repair;  
SUMOylation;  
post-translational modifications

†Present address: M. Moreno-Oñate, Andalusian Center for Developmental Biology, 41013 Sevilla, Spain.

**Abbreviations used:**

SUMO, Small Ubiquitin-like MOdifier; DSB, double-strand break; PTM, post-translational modification; SENP, SUMO-specific protease; LMB, leptomycin B; PLA, proximity ligation assay; MMS, methyl methanesulfonate; BER, base excision repair; HU, hydroxyurea; BSA, bovine serum albumin; PBS, phosphate-buffered saline.

**References**

- [1] T. Lindahl, Instability and decay of the primary structure of DNA, *Nature* 362 (1993) 709–715.
- [2] S.P. Jackson, J. Bartek, The DNA-damage response in human biology and disease, *Nature* 461 (2009) 1071–1078.
- [3] A. Tubbs, A. Nussenzweig, Endogenous DNA damage as a source of genomic instability in cancer, *Cell* 168 (2017) 644–656.
- [4] K. Bebenek, T. Kunkel, Functions of DNA polymerases, *Adv. Prot. Chem* 69 (2004) 137–165.
- [5] E.K. Braithwaite, P. Kedar, D.J. Stumpo, B. Bertocci, J.H. Freedman, L.D. Samson, S.H. Wilson, DNA polymerases beta and lambda mediate overlapping and independent roles in base excision repair in mouse embryonic fibroblasts, *PLoS One* 5 (2010), e12229.
- [6] G. Maga, G. Villani, E. Crespan, U. Wimmer, E. Ferrari, B. Bertocci, U. Hübscher, 8-Oxo-guanine bypass by human DNA polymerases in the presence of auxiliary proteins, *Nature* 447 (2009) 606–660.
- [7] B. van Loon, U. Hübscher, An 8-oxo-guanine repair pathway coordinated by MUTYH glycosylase and DNA polymerase lambda, *Proc. Natl. Acad. Sci. U. S. A.* 106 (2009) 18201–18206.
- [8] Capp, J-P., Boudsocq, F.; Bertrand, P., Laroche-Clary, A., Pourquier, P., Lopez, B.S., Cazaux, C., Hoffmann, J-S. and Canitrot, Y. (2006) The DNA polymerase lambda is required for the repair of non-compatible DNA double strand breaks by NHEJ in mammalian cells. *Nucleic Acids Res.* 34, 2998–3007.
- [9] J.M. Pryor, C.A. Waters, A. Aza, K. Asagoshi, C. Strom, P.A. Mieczkowski, L. Blanco, D.A. Ramsden, Essential role for polymerase specialization in cellular nonhomologous end joining, *Proc. Natl. Acad. Sci. U. S. A.* 112 (2015) E4537–E4545.
- [10] B. Bertocci, A. De Smet, J.C. Weill, C.A. Reynaud, Non-overlapping functions of DNA polymerases mu, lambda, and terminal deoxynucleotidyltransferase during immunoglobulin V(D)J recombination in vivo, *Immunity* 25 (2006) 31–41.
- [11] D. Lucas, B. Escudero, J.M. Ligos, J.C. Segovia, J.C. Estrada, G. Terrados, L. Blanco, E. Samper, et al., Altered hematopoiesis in mice lacking DNA polymerase mu is due to inefficient double-strand break repair, *PLoS Gen.* 5 (2009), e1000389.
- [12] B. van Loon, U. Hübscher, G. Maga, Living on the edge: DNA polymerase lambda between genome stability and mutagenesis, *Chem. Res. Toxicol.* 30 (2017) 1936–1941.
- [13] Wimmer, U., Ferrari, E., Hunziker, P. and Hübscher (2008) Control of DNA polymerase lambda stability by phosphorylation and ubiquitination during the cell cycle. *EMBO Rep.* 9,1027–1033.
- [14] I. Frouin, M. Touelle, E. Ferrari, I. Shevelev, U. Hübscher, Phosphorylation of human DNA polymerase lambda by the cyclin-dependent kinase Cdk2/cyclin A complex is modulated by its association with proliferating cell nuclear antigen, *Nucleic Acids Res.* 33 (2005) 5354–5361.
- [15] G. Sastre-Moreno, J.M. Pryor, M. Moreno-Oñate, A.M. Herrero-Ruiz, F. Cortés-Ledesma, L. Blanco, D.A. Ramsden, J.F. Ruiz, Regulation of human Polλ by ATM-mediated phosphorylation during non-homologous end joining, *DNA Repair* 51 (2017) 31–45.
- [16] A. Flotho, F. Melchior, Sumoylation: a regulatory protein modification in health and disease, *Annu. Rev. Biochem.* 82 (2013) 357–385.
- [17] S. Jentsch, I. Psakhye, Control of nuclear activities by substrate-selective and protein-group SUMOylation, *Annu. Rev. Genet.* 47 (2013) 167–186.
- [18] S.P. Jackson, D. Durocher, Regulation of DNA damage responses by ubiquitin and SUMO, *Mol. Cell* 49 (2013) 795–807.
- [19] P. Sarangi, X. Zhao, SUMO-mediated regulation of DNA damage repair and responses, *Trends in Biochem. Sci.* 40 (2015) 233–242.
- [20] G. Gill, SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? *Genes Dev.* 18 (2004) 2046–2059.
- [21] M.H. Tatham, E. Jaffray, O.A. Vaughan, J.M.P. Desterro, C.H. Botting, J.H. Naismith, R.T. Hay, Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9, *J. Biol. Chem.* 276 (2001) 35368–35374.
- [22] F. Ayaydin, M. Dasso, Distinct *in vivo* dynamics of vertebrate SUMO paralogues, *Mol. Biol. Cell* 15 (2004) 5208–5218.
- [23] H. Saitoh, J. Hinchey, Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3, *J. Biol. Chem.* 275 (2000) 6252–6258.
- [24] A.C.O. Vertegaal, J.S. Andersen, S.C. Ogg, R.T. Hay, M. Mann, A.I. Lamond, Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics, *Mol. Cell. Proteomics* 5 (2006) 2298–2310.
- [25] J.R. Gareau, C.D. Lima, The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition, *Nat. Rev. Mol Cell Biol.* 11 (2010) 861–871.
- [26] S. Wälde, K. Thakar, S. Hutten, C. Spillner, A. Nath, U. Rothbauer, S. Wiemann, R.H. Kehlenbach, The nucleoporin Nup358/RanBP2 promotes nuclear import in a cargo- and transport receptor-specific manner, *Traffic* 13 (2012) 218–233.
- [27] S.E. Schwarz, K. Matuschewski, D. Liakopoulos, M. Scheffner, S. Jentsch, The ubiquitin-like proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme, *Proc. Natl. Acad. Sci. U. S. A.* 95 (1998) 560–564.

- [28] I.A. Hendriks, L.W. Treffers, M. Verlaan-de Vries, J.V. Olsen, A.C. Vertegaal, SUMO2 orchestrates chromatin modifiers in response to DNA damage, *Cell Rep.* 10 (2015) 1778–1791.
- [29] I.A. Hendriks, D. Lyon, C. Young, L.J. Jensen, A.C.O. Vertegaal, M.L. Nielsen, Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation, *Nat. Str. Mol. Biol.* 24 (2017) 325–336.
- [30] E. Markkanen, B. van Loon, E. Ferrari, J.L. Parsons, G.L. Dianov, U. Hübscher, Regulation of oxidative DNA damage repair by DNA polymerase  $\lambda$  and MutYH by cross-talk of phosphorylation and ubiquitination, *Proc. Natl. Acad. Sci. U. S. A.* 109 (2012) 437–442.
- [31] R. Mahajan, C. Delphin, T. Guan, L. Gerace, F. Melchior, A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2, *Cell* 88 (1997) 97–107.
- [32] M. Watanabe, M. Fukuda, M. Yoshida, M. Yanagida, E. Nishida, Involvement of CRM1, a nuclear export receptor, in mRNA export in mammalian cells and fission yeast, *Genes Cells* 4 (1999) 291–297.
- [33] K. Takakusagi, Y. Takakusagi, K. Ohta, S. Aoki, F. Sugawara, K. Sakaguchi, A sulfoglycolipid beta-sulfoquinovosyldiacylglycerol (bSQDG) binds to Met1-Arg95 region of murine DNA polymerase lambda (Mmpol I) and inhibits its nuclear transit, *Protein Engineering, Design & Selection* 23 (2010) 51–60.
- [34] A.A. Stephenson, D.J. Taggart, Z. Suo, Noncatalytic, N-terminal domains of DNA polymerase lambda affect its cellular localization and DNA damage response, *Chem. Res. Toxicol.* 30 (2017) 1240–1249.
- [35] E.P. Rogakou, D.R. Pilch, A.H. Orr, V.S. Ivanova, W.M. Bonner, DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139, *J. Biol. Chem.* 273 (1998) 5858–5868.
- [36] W.M. Bonner, C.E. Redon, J.S. Dickey, A.J. Nakamura, O.A. Sedelnikova, S. Solier, Y. Pommier, GammaH2AX and cancer, *Nat. Rev. Cancer* 8 (12) (2008) 957–967.
- [37] T.W. Kirby, L.C. Pedersen, S.A. Gabel, N.R. Gassman, R.E. London, Variations in nuclear localization strategies among pol X family enzymes, *Traffic* 19 (2018) 723–735.
- [38] A. Pichler, A. Gast, J.-S. Seeler, A. Dejean, F. Melchior, The nucleoporin RanBP2 has SUMO1 E3 ligase activity, *Cell* 108 (2002) 109–120.
- [39] N. Saitoh, Y. Uchimura, T. Tachibana, S. Sugahara, H. Saitoh, M. Nakao, In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies, *Exp. Cell Res.* 312 (2006) 1418–1430.
- [40] A. Werner, A. Flotho, F. Melchior, The RanBP2/RanGAP1\*-SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase, *Mol. Cell* 46 (2012) 287–298.
- [41] G.L. Dianov, U. Hübscher, Mammalian base excision repair: the forgotten archangel, *Nucleic Acids Res.* 41 (2013) 3483–3490.
- [42] R.W. Sobol, J.K. Horton, R. Kühn, H. Gu, R.K. Singhal, R. Prasad, K. Rajewsky, S.H. Wilson, Requirement of mammalian DNA polymerase- $\beta$  in base-excision repair, *Nature* 379 (1996) 183–186.
- [43] E.K. Braithwaite, R. Prasad, D.D. Shock, E.W. Hou, W.A. Beard, S.H. Wilson, DNA polymerase lambda mediates a back-up base excision repair activity in extracts of mouse embryonic fibroblasts, *J. Biol. Chem.* 280 (18) (2005) 18469–18475.
- [44] U. Thapar, B. Demple, Deployment of DNA polymerases beta and lambda in single-nucleotide and multinucleotide pathways of mammalian base excision DNA repair, *DNA Repair (Amst)* 76 (2019) 11–19.
- [45] J.A. Tercero, J.F. Diffley, Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint, *Nature* 412 (2001) 553–557.
- [46] C.F. Chen, S. Li, Y. Chen, P.L. Chen, Z.D. Sharp, W.H. Lee, The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receiver, *J. Biol. Chem.* 271 (1996) 32863–32868.
- [47] L.I. Toledo, M. Murga, O. Fernandez-Capetillo, Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs, *Mol. Oncol.* 5 (2011) 368–373.
- [48] J.V. Forment, M.J. O'Connor, Targeting the replication stress response in cancer, *Pharmacol. Ther.* 188 (2018) 155–167.
- [49] E. Zucca, F. Bertolotti, U. Wimmer, E. Ferrari, G. Mazzini, S. Khoronenkova, N. Grosse, B. van Loon, et al., Silencing of human Pol $\lambda$  causes replication stress and is synthetically lethal with an impaired S phase checkpoint, *Nucleic Acids Res.* 41 (2012) 229–241.
- [50] R. Paul, S. Banerjee, M.M. Greenberg, Synergistic effects of an irreversible DNA polymerase inhibitor and DNA damaging agents on HeLa cells, *ACS Chem. Biol.* 12 (2017) 1576–1583.
- [51] A.S. Gowda, Z. Suo, T.E. Spratt, Honokiol inhibits DNA polymerases  $\beta$  and  $\lambda$  and increases bleomycin sensitivity of human cancer cells, *Chem. Res. Toxicol.* 30 (2017) 715–725.
- [52] M. van Overbeek, D. Capurso, M.M. Carter, M.S. Thompson, E. Frias, C. Russ, J.S. Reece-Hoyes, C. Nye, et al., DNA repair profiling reveals nonrandom outcomes at Cas9-mediated breaks, *Mol. Cell* 63 (2016) 633–646.
- [53] B.R. Lemos, A.C. Kaplan, J.E. Bae, A.E. Ferrazzoli, J. Kuo, R.P. Anand, D.P. Waterman, James E. Haber, CRISPR/Cas9 cleavages in budding yeast reveal templated insertions and strand-specific insertion/deletion profiles, *Proc. Natl. Acad. Sci. U. S. A.* 115 (2018) E2040–E2047.
- [54] J. Schimmel, H. Kool, R. van Schendel, M. Tijsterman, Mutational signatures of non-homologous and polymerase theta-mediated end-joining in embryonic stem cells, *EMBO J.* 36 (2017) 3634–3649.
- [55] M. Garcia-Diaz, O. Dominguez, L.A. Lopez-Fernandez, L.T. de Lera, M.L. Saniger, J.F. Ruiz, M. Parraga, M.J. Garcia-Ortiz, et al., DNA polymerase lambda (Pol lambda), a novel eukaryotic DNA polymerase with a potential role in meiosis, *J. Mol. Biol.* 301 (2000) 851–867.
- [56] R. González-Prieto, S.A. Cuijpers, M.S. Luijsterburg, H. van Attikum, A.C. Vertegaal, SUMOylation and PARylation cooperate to recruit and stabilize SLX4 at DNA damage sites, *EMBO Rep.* 16 (2015) 512–519.